Triptorelin embonate (6-month formulation): a guide to its use in advanced prostate cancer

Author：  

Publisher： Adis International

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.26, Iss.6, 2010-06, pp. : 5-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Triptorelin embonate: a 6-month formulation for prostate cancer

By Whelan Peter  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 17, 2010-12 ,pp. : 2929-2932

Informa Healthcare

Access to resources Recommend Favorite

Triptorelin Embonate (6-Month Formulation)

By Keating Gillian M.  

Drugs, Vol. 70, Iss. 3, 2010-02 ,pp. : 347-353

Adis International

Access to resources Recommend Favorite

Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer: An Open-Label, Non-Comparative, Multicentre, Phase III Study

By Lundström Eija A.  

Clinical Drug Investigation, Vol. 29, Iss. 12, 2009-12 ,pp. : 757-765

Adis International

Access to resources Recommend Favorite

Degarelix: a guide to its use in advanced prostate cancer

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 3, 2010-03 ,pp. : 6-8

Adis International

Access to resources Recommend Favorite

Degarelix: a guide to its use in advanced prostate cancer

By Lyseng-Williamson Katherine A.  

Drugs & Therapy Perspectives, Vol. 28, Iss. 5, 2012-05 ,pp. : 6-10

Adis International

Access to resources Recommend Favorite